Mirum Pharmaceuticals has reported top-line data from the Phase II EMBARK clinical trial of Livmarli (maralixibat) oral solution in biliary atresia patients.

The double-blind, randomised, placebo-controlled trial analysed the efficacy and safety of Livmarli versus placebo in biliary atresia patients following a Kasai surgery. 

Subjects enrolled in the trial were ≥21 days old and <90 days old during the time of the surgery with biliary atresia.

To be part of the trial, the participants should have undergone Kasai surgery within three weeks before randomisation in the trial.

Mean variation in total bilirubin over week 26 was the trial’s primary endpoint.

Proportion of subjects needing liver transplants or had some liver-associated event over this duration and mean variation in total serum bile acids were the trial’s secondary endpoints.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial failed to meet the primary endpoint and crucial secondary endpoints. 

Baseline characteristics were found to be proportionate across both arms of the trial. 

Livmarli was also found to be well-tolerated in the trial without any new safety findings reported.

Mirum Pharmaceuticals president and CEO Chris Peetz said: “We are disappointed in the outcome of the study in this post-surgery, high-need disease setting. 

“We are grateful to the patients, families, and clinicians who participated in the study and advanced the science around this rare liver disease.”

Mirum focuses on developing therapies for rare diseases that impact children and adults. 

Currently, three medications of the company, Livmarli oral solution, Cholbam capsules, and Chenodal tablets have received approvals for various indications.

In the US, Livmarli is indicated to treat cholestatic pruritus in Alagille syndrome patients. 

Cholbam is approved by the FDA to treat bile acid synthesis disorders while Chenodal is indicated for use under medical necessity recognition in cerebrotendinous xanthomatosis (CTX) patients.

In October 2023, Mirum reported positive data from the Phase III RESTORE trial of Chenodal tablets in CTX patients.